Organophosphates

New poll shows a strong base of Canadians overwhelmingly support controlled legal access to psilocybin-assisted therapy; Canadian Psychedelic Association responds with Memorandum of Regulatory Approval (MORA)

Retrieved on: 
Wednesday, August 4, 2021
Psychoactive drugs, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Psychedelic drug, Branches of biology

With public support at an all-time high, the CPA will now focus on introducing evidence-informed regulations to officials at Health Canada.

Key Points: 
  • With public support at an all-time high, the CPA will now focus on introducing evidence-informed regulations to officials at Health Canada.
  • Dr. Kryskow has witnessed firsthand what legal access to psychedelic medicine can do for Canadians in need of new treatment options.
  • Cory Firth, the Executive Director of the Canadian Psychedelic Association is confident the proposed amendments will continue our collaborative effort with Health Canada.
  • 82% of Canadians polled support or somewhat support approval for allowing the use of psilocybin-assisted therapy.

Mindset Files International Patent Application for its Novel Psilocybin Synthesis Method

Retrieved on: 
Tuesday, August 3, 2021
Entheogens, Psychoactive drugs, Psychoactive fungi, Mycotoxins, Organophosphates, Psilocybin

TORONTO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE:9DF) (OTCQB:MSSTF) (Mindset or the Company), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with unmet medical needs, today announced that it has filed an international patent application for its novel psilocybin synthesis method.

Key Points: 
  • TORONTO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE:MSET) (FSE:9DF) (OTCQB:MSSTF) (Mindset or the Company), a drug discovery and development company focused on creating optimized next-generation psychedelic medicines to treat neurological and neuropsychiatric disorders with unmet medical needs, today announced that it has filed an international patent application for its novel psilocybin synthesis method.
  • The application claims the priority date of the Companys previously filed United States Patent and Trade Office provisional application, filed on July 24, 2020.
  • The patent application covers Mindsets Synthesis Process, a ground-breaking process to synthesize psilocybin and psilocintwo of the known active compounds in psychedelic mushrooms.
  • We believe that our proprietary synthesis process is likely the most cost-effective method available in the marketplace today for cGMP grade psilocybin.

Core One’s Dr. Robert E.W. Hancock to Host Virtual Townhall Webcast and Present on Proprietary Biosynthesized Psilocybin Wednesday, August 4, 2021

Retrieved on: 
Friday, July 30, 2021
Hallucinations, Psychoactive drugs, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Branches of biology, Hallucinogen, Psychedelic drug

Dr. Hancock will be providing a presentation on the Companys proprietary biosynthesized psilocybin, its collaboration with the University of British Columbia, and the patenting process of its intellectual property.

Key Points: 
  • Dr. Hancock will be providing a presentation on the Companys proprietary biosynthesized psilocybin, its collaboration with the University of British Columbia, and the patenting process of its intellectual property.
  • Dr. Hancock will also be addressing questions received from investors at this live event.
  • The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin.
  • Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients.

Psychedelic Healthcare Innovation: PsiloThera Announces Launch of Quantum Technology Drug Development Program

Retrieved on: 
Friday, July 30, 2021
Entheogens, Psychoactive drugs, Fungi, Psychoactive fungi, Quantum mechanics, Organophosphates, Psilocybin, Quantum technology, Mushroom

HENDERSON, Nev., July 30, 2021 /PRNewswire/ -- PsiloThera, Inc. is a pioneering Psychedelic Healthcare Innovation& Life Sciences Company developing Psilocybin ("Magic Mushroom") based Drugs and Therapies proudly announces the launch of its Quantum Technology Drug Development Program.

Key Points: 
  • HENDERSON, Nev., July 30, 2021 /PRNewswire/ -- PsiloThera, Inc. is a pioneering Psychedelic Healthcare Innovation& Life Sciences Company developing Psilocybin ("Magic Mushroom") based Drugs and Therapies proudly announces the launch of its Quantum Technology Drug Development Program.
  • "Quantum Technology could ultimately change the way that Humans digest supplements, medications and nutrients."
  • "Quantum technology may lead to advances that could ultimately change the way that Humans digest supplements, medications and nutrients."
  • PsiloThera's outstanding battle tested management team will operate the Company's vertical business model which includes; Fungi Grow, Research & Development, Drug Development, Tele-Mental Health Platform and PsiloThera Treatment Centers.

Companies Smashing the Psychedelic Ceiling

Retrieved on: 
Thursday, July 29, 2021
Psychoactive drugs, Entheogens, Hallucinations, Mycotoxins, Organophosphates, Psilocybin, Psychedelic drug, Drug

Most psychedelic drug developers are working on drugs for mental illness, particularly depression; Tryp is targeting chronic pain and eating disorders.

Key Points: 
  • Most psychedelic drug developers are working on drugs for mental illness, particularly depression; Tryp is targeting chronic pain and eating disorders.
  • Tryp Therapeutics is advancing novel drug candidates made from psilocybin, the psychedelic component found in magic mushrooms.
  • Only an elite group of companies have initiated Phase 2 clinical trials exploring psychedelic-related compounds; those companies' valuation ranges from $85 million to $2.5 billion versus Tryp's $31 million.
  • To do so, Tryp has teamed up with leading companies whose expertise will be invaluable in its development.

Companies Smashing the Psychedelic Ceiling

Retrieved on: 
Thursday, July 29, 2021
Psychoactive drugs, Entheogens, Hallucinations, Mycotoxins, Organophosphates, Psilocybin, Psychedelic drug, Drug

NEW YORK, July 29, 2021 /PRNewswire/ -- It's early on in a burgeoning market, but there is certainly reason to be optimistic about the future of psychedelic medicines as a promising treatment for a broad spectrum of diseases and conditions. In fact, some breakthroughs may be closer than initially anticipated. After decades of stigma from their recreational use, psychedelics are now gaining momentum for medical applications as the U.S. Food and Drug Administration has signaled its intent to evaluate the compounds based on the merit of their clinical efficacy. The range of target indications is widening, the number of studies for different types of psychedelics is growing and specialized clinics are cropping up, a trio of signals that approved medical applications of psychedelics may be here before long. The diversity of approaches makes the market particularly interesting for psychedelic market participants. For instance, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (Profile) is studying how its novel technologies address chronic pain and eating disorders — two areas that have been particularly elusive for traditional drug makers. Seelos Therapeutics Inc. (NASDAQ: SEEL) is looking at a new spin on ketamine for certain types of depression, while Awakn Life Sciences Corp. (NEO: AWKN) and Field Trip Health Ltd. (TSX: FTRP) (OTCQX: FTRPF) are in the clinics and R&D businesses, and Small Pharma Inc. (TSX.V: DMT) is evaluating other psychedelics for depression.

Key Points: 
  • Most psychedelic drug developers are working on drugs for mental illness, particularly depression; Tryp is targeting chronic pain and eating disorders.
  • Tryp Therapeutics is advancing novel drug candidates made from psilocybin, the psychedelic component found in magic mushrooms.
  • Only an elite group of companies have initiated Phase 2 clinical trials exploring psychedelic-related compounds; those companies' valuation ranges from $85 million to $2.5 billion versus Tryp's $31 million.
  • To do so, Tryp has teamed up with leading companies whose expertise will be invaluable in its development.

Tryp Therapeutics Announces Q3 2021 Financial Results

Retrieved on: 
Thursday, July 29, 2021
Health sciences, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Pharmaceutical industry, Psychoactive drugs, Pharmaceutical sciences

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.

Key Points: 
  • Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.
  • Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience.
  • In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.
  • These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully.

DELIC Labs President and CSO Dr. Markus Roggen to Speak at MJBizCon

Retrieved on: 
Tuesday, July 27, 2021
Entheogens, Euphoriants, Medicinal plants, Psychoactive drugs, Branches of biology, Mycotoxins, Organophosphates, Psilocybin, Plants, Cannabis, Roggen

"Business managers find that cannabis production does not deliver on the riches promised, due to low yields or high costs," said Dr. Roggen, DELIC Labs President and CSO.

Key Points: 
  • "Business managers find that cannabis production does not deliver on the riches promised, due to low yields or high costs," said Dr. Roggen, DELIC Labs President and CSO.
  • Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Dr. Glenn Sammis, DELIC Labs supports the psychedelic industry with high precision chemical analytics, metabolomic identification and process optimization.
  • Dr. Markus Roggen is President and Chief Scientific Officer of Delic Labs, a licensed cannabis and psilocybin research laboratory focused on extraction optimization, analytical testing, and process development.
  • Delic Labs is one of a handful of research labs licensed for both cannabis and psilocybin in Canada.

Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor

Retrieved on: 
Monday, July 26, 2021
Hallucinations, Psychoactive drugs, Entheogens, Mycotoxins, Organophosphates, Psilocybin, Psychedelic drug, Hallucinogen, Branches of biology

Dr. Carhart-Harris has published over 100 papers in peer-reviewed scientific journals and is one of the most cited researchers in the medical application of psychedelic compounds.

Key Points: 
  • Dr. Carhart-Harris has published over 100 papers in peer-reviewed scientific journals and is one of the most cited researchers in the medical application of psychedelic compounds.
  • Tryp is also announcing the appointment of Daniel Clauw, M.D., as a member of the Scientific Advisory Board.
  • We welcome their continued scientific leadership as we advance the development of our PFN program toward approved therapies for patients."
  • Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.

Core One Labs to Present on its Proprietary Biosynthetic Psilocybin Technology at Investor Town Hall Event on August 4, 2021

Retrieved on: 
Sunday, July 18, 2021
Hallucinations, Psychoactive drugs, Entheogens, Psychedelic drugs, Branches of biology, Mycotoxins, Organophosphates, Psilocybin, Hallucinogen

The Virtual Town Hall event will comprise of a presentation by Dr. Hancock on the status of Vocans production of biosynthetic psilocybin and will include live video from the Companys operating laboratory in Victoria, British Columbia.

Key Points: 
  • The Virtual Town Hall event will comprise of a presentation by Dr. Hancock on the status of Vocans production of biosynthetic psilocybin and will include live video from the Companys operating laboratory in Victoria, British Columbia.
  • 2021 has been a significant year for Core One Labs, and our teams have been very focused on building a company that we truly feel sets precedent in the psychedelics space.
  • The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin.
  • Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients.